Cancel

nAMD and DME Management: Rapid Response From ARVO

Real-world outcomes with anti-vascular endothelial growth factor (VEGF) therapies in the management of patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) are often not comparable to those of clinical studies. Discrepancies in these outcomes have been associated with undertreatment due to high treatment burden and the associated loss of patient adherence to dosing schedules. Newer therapies with novel mechanisms that extend intervals between dosing...
This continuing education activity is provided by Vindico Medical Education.

nAMD and DME Management: Rapid Response From ARVO

Real-world outcomes with anti-vascular endothelial growth factor (VEGF) therapies in the management of patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) are often not comparable to those of clinical studies. Discrepancies in these outcomes have been associated with undertreatment due to high treatment burden and the associated loss of patient adherence to dosing schedules. Newer therapies with novel mechanisms that extend intervals between dosing...
This continuing education activity is provided by Vindico Medical Education.

Geographic Atrophy: Rapid Response from ARVO

Geographic atrophy (GA) is a pathological deterioration of the retina seen in the late stages of age-related macular degeneration (AMD). It affects 20% of people with AMD, and its prevalence increases exponentially with age. Until recently, there were no treatment options for GA, but investigation into the complement system and its role in the pathogenesis of GA has led to targeted therapies that have revolutionized the treatment paradigm. Because of the recent approval of one of these therapi...
This continuing education activity is provided by Vindico Medical Education.

Case Challenges in nAMD and DME Management: Achieving Durable Response

The management of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) with intravitreal anti-vascular endothelial growth factor (VEGF) therapies has provided enhanced visual outcomes for many patients. However, the high treatment burden associated with anti-VEGF therapies can lead to lack of patient adherence, resulting in suboptimal outcomes. Personalized treatment protocols using FDA-approved agents and newer novel delivery systems, along with agents with uni...
This continuing education activity is provided by Vindico Medical Education.

Meeting Milestones in nAMD and DME Management: What's New?

Anti-vascular endothelial growth factor (VEGF) therapy has revolutionized treatment paradigms for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). However, these agents are associated with a high treatment burden because of the injection frequency, and a substantial number of patients do not adhere to their treatment schedules, resulting in suboptimal response to therapy. To address these issues, new dosage regimens and surgical drug delivery approaches hav...
This continuing education activity is provided by Vindico Medical Education.

Ace the Case: An 84-Year-Old Man With Neovascular Age-Related Macular Degeneration Receiving Bilateral Every 8-Week Anti-Vascular Endothelial Growth Factor Injections

In this clinical case review, Dr. Emmanuel Chang explores options to extend treatment intervals in a patient with stable nAMD who is receiving anti-VEGF therapy every 8 weeks.
This continuing education activity is provided by Vindico Medical Education.

Ace the Case: A 76-Year-Old Male With Active Neovascular Age-Related Macular Degeneration

In this clinical case review, Dr. Arshad Khanani explores options for switching treatment in a patient with nAMD who has become nonresponsive to anti-vascular endothelial growth factor (VEGF) therapy.
This continuing education activity is provided by Vindico Medical Education.

The Art of Ophthalmology Medicine: Individualizing Therapy in Neovascular Age-Related Macular Degeneration in an Era of Expanded Treatment Options; AMD Virtual Pathways Activity

Target Audience This initiative is designed to meet the educational needs of retina/ophthalmology, optometry, managed care, primary care/internal medicine, diabetes education, and cardiology/endocrinology sub-specialties. Program Overview This enduring activity focuses on individualizing therapy for the treatment of neovascular age-related macular degeneration (nAMD) based on patient-, disease-, and treatment-related factors. Listen to a retina expert talk about some of the technological ...
Relias LLC

Recognition and Referral: Best Practices for Managing Patients with GA

Patients with advanced dry age-related macular degeneration can present with geographic atrophy (GA), a disease that is progressive and increases with age. Although there is no treatment approved by the FDA that halts or reverses GA, a number of drugs in the pipeline are designed to address GA progression, hoping to succeed where previous drug candidates failed. This series of regional, interactive, virtual symposia are designed to educate eye care providers on the importance of diagnosis and ...
Evolve Medical Education LLC

The Art of Ophthalmology Medicine: Individualizing Therapy in Neovascular Age Related Macular Degeneration in an Era of Expanded Treatment Options; nAMD Day in the Life

Target Audience This initiative is designed to meet the educational needs of retina/ophthalmology, optometry, managed care, primary care/internal medicine, diabetes education, and cardiology/endocrinology sub-specialties. Program Overview This enduring activity focuses on individualizing therapy for the treatment of neovascular age-related macular degeneration (nAMD). Providers will learn about the safety, efficacy, and durability of established and emerging nAMD therapies, as well as tec...
Relias LLC

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map